Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 7/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289498 | 0.94 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1FAAH | |
| SCHEMBL13121510 | 0.92 | GSK3B (0.69) | GSK3BCDK2CCNE1 | |
| SCHEMBL14043233 | 0.90 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1CDK9 | |
| SCHEMBL12954095 | 0.89 | GSK3B (0.54) | GSK3BCHEK1MEN1KMT2ACDK2 | |
| SCHEMBL14043406 | 0.89 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1FAAH | |
| SCHEMBL12954329 | 0.88 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL14613416 | 0.88 | GSK3B (0.52) | GSK3BCHEK1CDK2CCNE1CDK9 | |
| SCHEMBL13289145 | 0.87 | GSK3B (0.53) | GSK3BCHEK1MEN1KMT2ACDK2 | |
| SCHEMBL12954326 | 0.87 | GSK3B (0.58) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13288814 | 0.86 | GSK3B (0.61) | GSK3BCHEK1CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |